We are live on ! Find out more
Daiwa Securities Group

Daiwa Securities Group Portfolio holdings

AUM $34.8B
1-Year Est. Return 20.7%
This Fund
S&P 500
This Quarter Est. Return
+7.46%
1 Year Est. Return
+20.7%
3 Year Est. Return
+66.64%
5 Year Est. Return
+79.21%
10 Year Est. Return
+192.59%
AUM
$29.6B
AUM Growth
+$2.54B
Cap. Flow
+$740M
Cap. Flow %
2.5%
Top 10 Hldgs %
36.41%
Holding
1,385
New
83
Increased
652
Reduced
368
Closed
52

Top Buys

Rank Stock Value
1
CRWD icon
CrowdStrike
CRWD
+$163M
2
NOW icon
ServiceNow
NOW
+$139M
3
ELS icon
Equity Lifestyle Properties
ELS
+$137M
4
CCI icon
Crown Castle
CCI
+$118M
5
NFLX icon
Netflix
NFLX
+$115M

Sector Composition

Rank Sector Weight
1 Technology 30%
2 Real Estate 28.67%
3 Communication Services 10.86%
4 Consumer Discretionary 6.91%
5 Financials 5.91%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
DAWN
1251
DELISTED
Day One Biopharmaceuticals
DAWN
$2K ﹤0.01%
296
EOLS icon
1252
Evolus
EOLS
$397M
$2K ﹤0.01%
262
ERAS icon
1253
Erasca
ERAS
$6.15B
$2K ﹤0.01%
1,074
ESPR
1254
DELISTED
Esperion Therapeutics
ESPR
$2K ﹤0.01%
650
EYPT icon
1255
EyePoint Inc
EYPT
$999M
$2K ﹤0.01%
144
FDMT icon
1256
4D Molecular Therapeutics
FDMT
$502M
$2K ﹤0.01%
184
LKFT
1257
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$2K ﹤0.01%
51
GLUE icon
1258
Monte Rosa Therapeutics
GLUE
$1.82B
$2K ﹤0.01%
203
IBB icon
1259
iShares Biotechnology ETF
IBB
$9.45B
$2K ﹤0.01%
12
-912
-99% -$124K
IOVA icon
1260
Iovance Biotherapeutics
IOVA
$2.04B
$2K ﹤0.01%
1,006
KALV
1261
DELISTED
KalVista Pharmaceuticals
KALV
$2K ﹤0.01%
154
KROS icon
1262
Keros Therapeutics
KROS
$197M
$2K ﹤0.01%
133
LXRX icon
1263
Lexicon Pharmaceuticals
LXRX
$1.03B
$2K ﹤0.01%
1,369
MESO
1264
Mesoblast
MESO
$1.83B
$2K ﹤0.01%
105
NRIX icon
1265
Nurix Therapeutics
NRIX
$2.45B
$2K ﹤0.01%
245
OLMA icon
1266
Olema Pharmaceuticals
OLMA
$977M
$2K ﹤0.01%
224
PAHC icon
1267
Phibro Animal Health
PAHC
$1.5B
$2K ﹤0.01%
38
PGEN icon
1268
Precigen
PGEN
$1.94B
$2K ﹤0.01%
708
PRME icon
1269
Prime Medicine
PRME
$547M
$2K ﹤0.01%
398
PRTA icon
1270
Prothena Corp
PRTA
$448M
$2K ﹤0.01%
195
RIGL icon
1271
Rigel Pharmaceuticals
RIGL
$723M
$2K ﹤0.01%
80
SIGA icon
1272
SIGA Technologies
SIGA
$240M
$2K ﹤0.01%
270
SLDB icon
1273
Solid Biosciences
SLDB
$792M
$2K ﹤0.01%
400
SVRA icon
1274
Savara
SVRA
$1.08B
$2K ﹤0.01%
553
TKNO icon
1275
Alpha Teknova
TKNO
$266M
$2K ﹤0.01%
300

Similar funds

Daiwa Securities Group's Q3 2025 Portfolio in Review

As of Q3 2025, Daiwa Securities Group held 1,385 positions worth $29.6B, up 9.4% from $27.1B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Daiwa Securities Group's Q3 2025 filing shows 83 new, 652 increased, 368 reduced and 52 closed positions. Its largest new stake was Eagle Materials: 54,795 shares worth $12.8M. The largest sale was Global X Conscious Companies ETF, an estimated $130M.

By sector, the portfolio is most concentrated in Technology at 30% of assets, up from 28% a quarter earlier, followed by Real Estate and Communication Services.

  • Daiwa Securities Group's largest Q3 2025 buy was Eagle Materials: 54,795 shares worth $12.8M.
  • Daiwa Securities Group added most to CrowdStrike in Q3 2025, an estimated $163M increase.
  • Daiwa Securities Group's biggest Q3 2025 reduction was Global X Conscious Companies ETF, cutting an estimated $130M.
  • Daiwa Securities Group fully exited Ansys in Q3 2025, selling an estimated $6.94M.
  • Daiwa Securities Group's ten largest holdings make up 36% of its $29.6B portfolio in Q3 2025.
  • Daiwa Securities Group opened 83 new positions and closed 52 in Q3 2025.
  • Daiwa Securities Group's portfolio value rose 9.4% quarter-over-quarter to $29.6B.

Based on Daiwa Securities Group's 13F filing for Q3 2025, filed 14 Nov 2025.